Journal Scans
Predictive Markers of Anthracycline Benefit: A Prospectively Planned Analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
Predictive Markers of Anthracycline Benefit in Breast Cancer
JMS Bartlett, AF Munro, JA Dunn, C McConkey, S Jordan, CJ Twelves, DA Cameron, J Thomas, FM Campbell, DW Rea, E Provenzano, C Caldas, P Pharoah, L Hiller, H Earl, CJ Poole
20100201
2010 Mar 1
Lancet Oncol
Predictive Markers of Anthracycline Benefit: A Prospectively Planned Analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
Lancet Oncol. 2010 Mar 1;11(3):266-274, JMS Bartlett, AF Munro, JA Dunn, C McConkey, S Jordan, CJ Twelves, DA Cameron, J Thomas, FM Campbell, DW Rea, E Provenzano, C Caldas, P Pharoah, L Hiller, H Earl, CJ Poole
TAKE-HOME MESSAGE
Abstract
Abstract
Background: The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A. Methods: 1941 tumours from 2391 women recruited to NEAT/BR9601 were analysed on tissue microarrays for HER2 and TOP2A amplification and deletion, HER1—3 and Ki67 expression, and duplication of chromosome 17 centromere...
